AbbVie’s Venclyxto Receives the EC’s Approval for Patients with Newly Diagnosed Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

 AbbVie’s Venclyxto Receives the EC’s Approval for Patients with Newly Diagnosed Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

AbbVie’s Rinvoq (upadacitinib) Receives EC’s Approval for the Treatment of Moderate to Severe Atopic Dermatitis

Shots:

  • The approval is based on P-III VIALE-A and P-Ib M14-358 studies. The P-III study involves assessing Venclyxto + azacitidine in patients with newly diagnosed AML who were ineligible for intensive CT and demonstrated OS (14.7mos. vs 9.6mos.), CCCR (66.4% vs 28.3%), CR (36.7% vs 17.9%)
  • The P-Ib M14-358 trial involves assessing in Venclyxto + azacytidine or decitabine in patients with newly diagnosed AML who were ineligible for intensive CT and showed CR+CRi rate (74%), 30-day mortality rate (6.5%)
  • In Apr’2021, Venclyxto + hypomethylating agents receive CHMP’s positive opinion for MAA to treat newly diagnosed AML patients who are ineligible for intensive CT

Click here to­ read full press release/ article | Ref: Abbvie | Image: Pharma Live

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post